Eletriptan |
Relpax |
Article: Eletriptan
| Image:Eletriptan.png | |
| Eletriptan | |
| Systematic (IUPAC) name | |
| 3-[(1-methylpyrrolidin-2-yl) methyl]-5- (2-phenylsulfonylethyl)- 1H-indole | |
| Identifiers | |
| CAS number | 143322-58-1 |
| ATC code | N02CC06 |
| PubChem | 77993 |
| DrugBank | APRD00945 |
| Chemical data | |
| Formula | C22H26N2O2S |
| Mol. weight | 382.52 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Eletriptan (Relpax®) is a triptan drug developed by Pfizer for the treatment of migraine headaches. It is available in strengths of 20 and 40 mg as a tablet.
Eletriptan is available only by prescription in the United States and Canada.
Chemical name: (R)-5-[2-(Fenylsulfonyl)etyl]-3-[(1-metyl-2-pyrrolidinyl)metyl]-1H-indol
Resources
- Eletriptan (Drug Digest)
- Relpax (Drug Digest)

Not Signed In -


